

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

**A Phase III, multicenter, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-Aflibercept (CinnaGen Co, Iran) to the reference Aflibercept product (Eylea®, Regeneron, USA) in patients with Neovascular age-related macular degeneration.**

### Protocol summary

#### Study aim

The aim of this study is to assess non-inferiority of Aflibercept (CinnaGen co.) to Eylea® (Regeneron, USA) in terms of achieving maintaining vision in patients with neovascular age-related macular degeneration.

#### Design

This is a phase III, randomize, parallel, double-blind and active-control with the sample size of 168 patients.

#### Settings and conduct

This is a multicenter, phase 3 clinical trial

#### Participants/Inclusion and exclusion criteria

Patients aged 55-80 years with primary active CNV subfoveal lesion secondary to AMD (according to the physician's decision based on the results of ocular examination, or OCT) and the ETDRS-best-corrected visual acuity index with the score of 20/40 to 20/320 with include to the study. This study has 34 exclusion criteria which include any prior ocular or systemic anti-VEGF therapy during the past 3 months, presence of scar, fibrosis, or atrophy in the central part of the fovea in the study eye, active intraocular inflammation in either eye and histories such as the history or evidence of diabetic retinopathy, diabetic macular edema and the history of uveitis in either eye.

#### Intervention groups

Intervention group 1: Aflibercept (CinnaGen Co, Iran) 2 mg by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study. Intervention group 2: Eylea (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks (Monthly) for the first 3 injections, followed by 2 mg every 8 weeks (every two months) Until week 48 of study.

#### Main outcome variables

Assessing the main outcome is based on evaluating visual acuity with Tumbling-E ETDRS chart

### General information

#### Reason for update

- The secondary endpoint number 2 is revised to "The percentage of patients who have increase of  $\geq 15$  score on ETDRS chart at week 52 visit compared to baseline". - The timepoints for the assessment of laboratory parameters is changed to the screening visit, week 24, and week 52. - "visit 0" is changed to visit 1 (baseline visit (week 0)). - Inactive study centers are removed and new centers/investigators are added to increase patient recruitment rate.

#### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20150303021315N14**  
Registration date: **2019-06-30, 1398/04/09**  
Registration timing: **prospective**

Last update: **2020-11-24, 1399/09/04**

Update count: **1**

#### Registration date

2019-06-30, 1398/04/09

#### Registrant information

##### Name

Nassim Anjidani

##### Name of organization / entity

Orchid Pharmed

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 4347 3000

##### Email address

**Recruitment status**

**Recruitment complete**

**Funding source**

**Expected recruitment start date**

2019-07-23, 1398/05/01

**Expected recruitment end date**

2020-03-19, 1398/12/29

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

A Phase III, multicenter, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of test-Aflibercept (CinnaGen Co, Iran) to the reference Aflibercept product (Eylea®, Regeneron, USA) in patients with Neovascular age-related macular degeneration.

**Public title**

The Effect of Aflibercept on Treatment of Age-related macular Degeneration

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

male or female aged 55-80 years at the time of signing the informed consent form. Patients with Primary active CNV subfoveal lesion secondary to AMD (with definite diagnosis of AMD according to physician's decision based on the results of ocular examination, or OCT) the ETDRS-best-corrected visual acuity index with the score of 20/40 to 20/320 (or BCVA letter score of 73 to 25 in the study eye) Willing, committed, and able to return for clinic visits and complete all study-related procedures Patients with the ability to read, understand and willing to sign the informed consent form for participation in the study

**Exclusion criteria:**

Any prior ocular (in the study eye) or systemic anti-VEGF therapy, during the past 3 months, Photodynamic Therapy (PDT) or surgery for neovascular AMD. The need for receiving ocular anti-VEGF simultaneously in both eyes in the loading phase for the treatment of neovascular AMD Scar, fibrosis, or extensive subretinal hemorrhage of more than 50% of the total lesion area in the study eye, according to the physician's opinion based on clinical presentation or according to fundus photography. The presence of scar, fibrosis, or atrophy in the central part of the fovea in the study eye The presence of retinal pigment epithelial tears or rips involving the macular part of the study eye at the time of entering the study The history of any vitreous hemorrhage within 4 weeks prior to the first visit of the study in the study eye Presence of other causes of CNV in the study eye Clinical or paraclinical diagnosis of PCV by physician's diagnosis The history or clinical evidence of diabetic retinopathy, diabetic macular edema, or any

other vascular disease affecting the retina, other than AMD in either eyes Prior vitrectomy in the study eye History of retinal detachment or treatment or surgery for retinal detachment in the study eye Any history of a macular hole of stage 2 or above in the study eye Any intraocular or periocular surgery within three months of the screening visit on the study eye except lid surgery, which may not have taken place within one month of screening visit Prior trabeculectomy or any other filtration surgery in the study eye Uncontrolled glaucoma (defined as intraocular pressure  $\geq$  25 mmHg despite treatment with anti-glaucoma medication) in the study eye Active intraocular inflammation in either eye Active ocular or periocular infection in either eye or any ocular or periocular infection within the last two weeks prior to screening visit in either eye Any history of uveitis in either eye Presence or history of scleromalacia in either eye Aphakia or pseudophakia with the absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye Previous therapeutic radiation in the region of the study eye History of corneal transplant or corneal dystrophy in the study eye Any significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of drug safety, or fundus photography Patients with amblyopia. Patients with blindness in the fellow eye Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could require either medical or surgical intervention during the study period Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk for treatment complications Participation as a patient in any clinical study within the 12 weeks prior to the screening visit The use of long-acting steroids, either systemically or intraocularly, in the six months prior to screening visit Any history of allergy to povidone iodine Females who are pregnant, breastfeeding, planning to become pregnant during the study period, unwilling to practice adequate contraception throughout the study and for at least 60 days following the last dose of study medication History of stroke, myocardial infarction or uncontrolled hypertension (blood pressure  $>$ 160/100 despite receiving medical treatment) for less than three months from the date of the Screening visit Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders

**Age**

From **55 years** old to **80 years** old

**Gender**

Both

## Phase

3

## Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

## Sample size

Target sample size: **168**

## Randomization (investigator's opinion)

Randomized

## Randomization description

The randomization plan of the patients will be carried out centrally using an R-CRAN software version 3.2.3. Blocks (with the size 2 or 4) will be made using permuted block randomization for a total of 168 patients (1:1 allocation ratio). After the randomization procedure, a code will be allocated to each patient that will be used as a patient identifier throughout the study. The assigned code will be denoted by 4 initials (corresponding to the first two letters of the first name, first two letters of surname) and 3 numbers (center code). Moreover, the described code is followed by study unique identification code consisting of first three letters of the generic name of the investigational product (AFL), and three numbers (corresponding to the randomization number), e.g. ABCD001AFL-001. The randomization number will be assigned in a consecutive way.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

Both Aflibercept products used in the study will be entirely indistinguishable for patients and health care providers since they are identical in shape, size, label, and color. The container of the drugs will be labeled using identical Labels so they will be impossible to differentiation. Patients groups and their drugs will not be disclosed to investigators. After that, the patient signed Informed consent and considered to be eligible base on the inclusion and exclusion criteria; he or she will be allocated to one of each group. The investigator will not be informed of randomization, and all the drug codes will be placed in an opaque pocket inside each sites trial Master file. Data analyzers will not be informed of the patients' grouping.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

## Name of ethics committee

The Ethics Committee of Tehran University of Medical Sciences

## Street address

Qods St., Keshavarz Blvd

## City

Tehran

## Province

Tehran

## Postal code

1417653761

## Approval date

2019-05-07, 1398/02/17

## Ethics committee reference number

IR.TUMS.VCR.REC.1398.116

## Health conditions studied

### 1

#### Description of health condition studied

Neovascular age-related macular Degeneration

#### ICD-10 code

H35.32

#### ICD-10 code description

Exudative age-related macular degeneration

## Primary outcomes

### 1

#### Description

The proportion of patients achieving maintaining vision (losing <15 letter on ETDRS chart) at week 52, in comparison to visit 0.

#### Timepoint

baseline visit, 52 weeks after first intervention

#### Method of measurement

Tumbling-E ETDRS chart

## Secondary outcomes

### 1

#### Description

Mean changes in the Best-Corrected Visual Acuity Index measured with ETDRS chart from visit baseline to week 52

#### Timepoint

baseline visit and 52 weeks after first intervention

#### Method of measurement

Tumbling E ETDRS chart

### 2

#### Description

The percentage of patients who have increase of  $\geq 15$  score in ETDRS at week 52

#### Timepoint

baseline visit and 52 weeks after first intervention

#### Method of measurement

Tumbling E ETDRS chart

### 3

#### **Description**

The mean change in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at week 52 compared to the visit baseline.

#### **Timepoint**

Baseline Visit and 52 weeks after first intervention

#### **Method of measurement**

NEI VFQ-25

### 4

#### **Description**

Mean changes in central retinal thickness based on structural OCT at week 52 compared to the screening visit

#### **Timepoint**

screening visit and 52 weeks after first intervention

#### **Method of measurement**

Optical Coherence Tomography (OCT)

### 5

#### **Description**

The percentage of patients without intra-retinal fluid and subretinal fluid based on structural OCT at week 52

#### **Timepoint**

52 weeks after first intervention

#### **Method of measurement**

Optical Coherence tomography

### 6

#### **Description**

Systemic and Ophthalmic Adverse events (AEs) and adverse drug reactions (ADR) – at screening, visit 1 and all the follow-up visits until week 52

#### **Timepoint**

All of the study visits

#### **Method of measurement**

Physical examination

### 7

#### **Description**

Comparing immunogenicity of two products and evaluating antibody formation- at screening visit, week 24 and week 52.

#### **Timepoint**

screening visit, 24 weeks, and 52 weeks after first intervention

#### **Method of measurement**

ELISA Assay

### 8

#### **Description**

Evaluation of blood pressure- at screening visit and week 52

#### **Timepoint**

Screening Visit, 52 weeks after first intervention

#### **Method of measurement**

blood pressure meter

### 9

#### **Description**

Clinical laboratory testing for systemic safety, including liver and kidney functions, complete blood count and clinical bio-chemistries- at regular intervals

#### **Timepoint**

screening visit, 24 weeks and 52 weeks after first intervention

#### **Method of measurement**

Lab test

### 10

#### **Description**

Changes in physical examination findings- at screening visit and week 52

#### **Timepoint**

Screening Visit, and 52 weeks after first intervention

#### **Method of measurement**

Physical examination

## **Intervention groups**

### 1

#### **Description**

Aflibercept (CinnaGen Co, Iran) 2 mg (0.05 mL) by intravitreal injection every 4 weeks (Monthly) for the first 3 injections, followed by 2 mg every 8 weeks (every two months) Until week 48 of study

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Eylea (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks (Monthly) for the first 3 injections, followed by 2 mg every 8 weeks (every two months) Until week 48 of study.

#### **Category**

Treatment - Drugs

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Farabi Hospital

##### **Full name of responsible person**

Dr. Reza Karkhane

##### **Street address**

Kargar Jonobi, District 11, Tehran

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

1336616351

##### **Phone**

+98 21 5540 0003

**Fax**  
+98 21 5541 0520  
**Email**  
farabih@tums.ac.ir  
**Web page address**  
<http://farabih.tums.ac.ir/>

## 2

### Recruitment center

**Name of recruitment center**  
Rasool Akram Hospital  
**Full name of responsible person**  
Dr. Khalil Ghasemi Falavarjani  
**Street address**  
SatarKhan St., District 2, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1445613131  
**Phone**  
+98 21 6651 5001  
**Email**  
hrmc@iums.ac.ir  
**Web page address**  
<http://hrmc.iums.ac.ir/>

## 3

### Recruitment center

**Name of recruitment center**  
Khatamolanbia Hospital  
**Full name of responsible person**  
Dr. Naser Shoeybi  
**Street address**  
Qarani Ave., Mashhad  
**City**  
Mashhad  
**Province**  
Razavi Khorasan  
**Postal code**  
45986520  
**Phone**  
+98 51 3728 1401  
**Email**  
info@khatamhospital.org  
**Web page address**  
<https://www.khatamhospital.org/>

## 4

### Recruitment center

**Name of recruitment center**  
Negaah eye hospital  
**Full name of responsible person**  
Dr. Mahdi Modareszadeh  
**Street address**  
Ketabi St., Shariati St., Tehran  
**City**  
Tehran  
**Province**

Tehran  
**Postal code**  
1544914599  
**Phone**  
+98 21 23555  
**Email**  
info@Negaheyehospital.com  
**Web page address**  
<http://negaheyehospital.com>

## 5

### Recruitment center

**Name of recruitment center**  
Central eye clinic  
**Full name of responsible person**  
Dr. Khalil Ghasemi Falavarjani  
**Street address**  
Shahid St., Vanaq Square, Valiasr St.,  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
5465465  
**Phone**  
+98 21 8867 7652  
**Email**  
hrmc@iums.ac.ir  
**Web page address**

## 6

### Recruitment center

**Name of recruitment center**  
Amir Al Mo'menin Educational Remedial & Research  
Center  
**Full name of responsible person**  
Dr. Yousef Alizadeh  
**Street address**  
17 th Shahrivar, Imam Khomeini St., Rasht  
**City**  
Rasht  
**Province**  
Guilan  
**Postal code**  
1113351313  
**Phone**  
+98 13 3323 8306  
**Email**  
amiralmomenin@gums.ac.ir  
**Web page address**  
<http://www.gums.ac.ir/amir/>

## 7

### Recruitment center

**Name of recruitment center**  
Feiz Hospital  
**Full name of responsible person**  
Dr. Farhad Fazel Najafabadi  
**Street address**  
Modares St., Isfahan

**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
641030132  
**Phone**  
+98 31 3303 3460  
**Email**  
info@feiz.mui.ac.ir  
**Web page address**  
<http://feiz.mui.ac.ir/>

## 8

### Recruitment center

**Name of recruitment center**  
Imam Khomeini Hospital  
**Full name of responsible person**  
Dr. Hamid Aryaeitabar  
**Street address**  
Naqlih St., Kermanshah  
**City**  
Kermanshah  
**Province**  
Kermanshah  
**Postal code**  
6718743161  
**Phone**  
+98 83 3728 3602  
**Email**  
ihosp@kums.ac.ir  
**Web page address**  
<https://imamkhomeini.kums.ac.ir/>

## 9

### Recruitment center

**Name of recruitment center**  
Imam Khomeini Hospital  
**Full name of responsible person**  
Dr. Mostafa Fegghi,  
**Street address**  
Azadegan St., Ahwaz  
**City**  
Ahwaz  
**Province**  
Khouzestan  
**Postal code**  
6193673111  
**Phone**  
+98 61 3222 2114  
**Fax**  
+98 61 3222 2114  
**Email**  
himam@ajums.ac.ir  
**Web page address**  
<http://himam.ajums.ac.ir>

## 10

### Recruitment center

**Name of recruitment center**

Bisotoon Hospital  
**Full name of responsible person**  
Dr. Hamid Aryaeitabar  
**Street address**  
Keyhanshahr Blvd- Kermanshah  
**City**  
kermanshah  
**Province**  
Kermanshah  
**Postal code**  
67196-88345  
**Phone**  
+98 83 3832 1701  
**Fax**  
+98 83 3832 3773  
**Email**  
bistoon.hospital.kermanshah.iran@gmail.com

## 11

### Recruitment center

**Name of recruitment center**  
Poustchi Clinic  
**Full name of responsible person**  
Dr.Hossein Norouzzadeh  
**Street address**  
Zand Blvd- Shiraz  
**City**  
Shiraz  
**Province**  
Fars  
**Postal code**  
71348-14336  
**Phone**  
+98 71 3233 0073  
**Fax**  
+98 71 3233 0073  
**Email**  
poostchi@sums.ac.ir

## 12

### Recruitment center

**Name of recruitment center**  
Aban Clinic  
**Full name of responsible person**  
Dr.Farhad Fazel  
**Street address**  
Isfahan-Sajjad St.-Qayyam Farahani St  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
81746-73461  
**Phone**  
+98 31 3630 5035  
**Fax**  
+98 31 3630 5036  
**Email**  
gh.mehrvar@gmail.com

## 13

### Recruitment center

**Name of recruitment center**

universityspecial@gmail.com

**Full name of responsible person**

Dr.Hamid Aryaeitabar

**Street address**

Pardis Sq-Kermanshah

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6713954658

**Phone**

+98 83 3720 1646

**Email**

universityspecial@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

CinnaGen company

**Full name of responsible person**

Dr. Haleh Hamedifar

**Street address**

CinnaGen research and production Company. Simin  
Dasht Industrial Park, Karaj, Alborz, Iran

**City**

karaj

**Province**

Alborz

**Postal code**

3165933155

**Phone**

+98 26 3667 0980

**Email**

cinnagen@cinnagen.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

CinnaGen company

**Proportion provided by this source**

100

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Industry

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Orchid Pharmed Co.

**Full name of responsible person**

Dr. Nasim Anjidani

**Position**

medical department manager

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

No 42, Atar S.q, Atar St., Vanak S.q, Valiasr St.,  
Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

19947766411

**Phone**

+98 21 8808 8821

**Email**

anjidani.n@orchidpharmed.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Reza Karkhane

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Ophthalmology

**Street address**

Farabi Hospital, Kargar Jonoobi St., District 11

**City**

Tehran

**Province**

Tehran

**Postal code**

1336616351

**Phone**

+98 21 5540 0003

**Email**

Karkhane@tums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

شرکت ارکیدفارمد

**Full name of responsible person**

Dr. Nassim Anjidani

**Position**

Pharmacist, Clinical Trial Manager

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

No 42, Atar S.q, Atar St., Vanak S.q, Valiasr St.,  
Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

19947766411

**Phone**

+98 21 8808 8821

**Email**

Anjidani.N@orchidpharmed.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Not applicable

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available